Intermediate uveitis.
Intermediate uveitis (IU) is described as inflammation in the anterior vitreous, ciliary body and the peripheral retina. In the Standardization of Uveitis Nomenclature (SUN) working group's international workshop for reporting clinical data the consensus reached was that the term IU should be used for that subset of uveitis where the vitreous is the major site of the inflammation and if there is an associated infection (for example, Lyme disease) or systemic disease (for example, sarcoidosis). The diagnostic term pars planitis should be used only for that subset of IU where there is snow bank or snowball formation occurring in the absence of an associated infection or systemic disease (that is, "idiopathic"). This article discusses the clinical features, etiology, pathogenesis, investigations and treatment of IU.
Babu
B Manohar
BM
Uvea Clinic, Aravind Eye Hospital, Coimbatore, India.
Rathinam
S R
SR
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D017679:Cryotherapy / Q000379:methods*; D003937:Diagnosis, Differential; D005451:Fluorescein Angiography / Q000379:methods; D005654:Fundus Oculi; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D033401:Microscopy, Acoustic / Q000379:methods; D009887:Ophthalmoscopy / Q000379:methods; D011379:Prognosis; D013601:T-Lymphocytes / Q000276:immunology*; D015867:Uveitis, Intermediate / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D014821:Vitrectomy / Q000379:methods*
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents